Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a Histone 3 K27M (H3 K27M) mutation
Philadelphia, PA (January 14, 2019) –Oncoceutics Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a Histone 3 K27M (H3 K27M) mutation. This patent extends the ONC201 patent life through at least 2038.
This patent is the eighth issued on ONC201 in the United States, and expands the IP protection the company has received covering the compound’s use in cancer. These patents, combined with issued patents around the compound’s formulation and use in combination with other therapies, as well as FDA regulatory designations, provide ONC201 with a robust suite of intellectual property.
ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical models and ongoing clinical trials, including multiple clinical trials in adult and pediatric patients harboring this mutation, funded by grants from the NCI. These trials are being carried out at Massachusetts General Hospital, Dana Farber Cancer Institute, NYU Langone, MD Anderson Cancer Center, Levine Cancer Institute, Miami Cancer Institute, UCSF, and the University of Michigan. Recently, the FDA granted Fast Track Designation to ONC201 for the Treatment of Adult Recurrent H3 K27M-mutant High-Grade Glioma.
“We are delighted that the USPTO has recognized these indications as novel uses of ONC201 and granted the appropriate patent protections,” said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. “The company’s current patent portfolio provides Oncoceutics more than 19 years of patent protection for the vast majority of human cancers, including tumor types where ONC201 is currently in Phase II trials.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, i.e. the “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist. The company is supported by grants from NCI, FDA, Musella Foundation, XCures, Cancer Commons, and a series of private and public partnerships.
